Allena Pharmaceuticals, Inc. (ALNAQ)

OTCMKTS: ALNAQ · Delayed Price · USD
0.0140
+0.0015 (12.00%)
Dec 2, 2022 4:00 PM EST - Market closed
12%
Market Cap 1.53M
Revenue (ttm) n/a
Net Income (ttm) -8.44M
Shares Out 122.08M
EPS (ttm) -0.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,197,509
Open 0.0125
Previous Close 0.0125
Day's Range 0.01 - 0.014
52-Week Range 0.01 - 0.2154
Beta 1.36
Analysts Sell
Price Target n/a
Earnings Date Dec 2, 2022

About ALNAQ

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for... [Read more]

Industry Biotechnology
IPO Date Nov 2, 2017
CEO Louis Brenner
Employees 12
Stock Exchange OTCMKTS
Ticker Symbol ALNAQ
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
n/a
Analyst Consensus: Sell
Stock Forecasts

News

Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split

NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

4 months ago - GlobeNewsWire

Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split

NEWTON, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

4 months ago - GlobeNewsWire

Why Shares Of Allena Pharmaceuticals Are Skyrocketing Today

Shares of small-cap penny stock Allena Pharmaceuticals (NASDAQ: ALNA) shares are trading higher after the company announced it has terminated its previously announced at-the-market offering. Allena Phar...

5 months ago - Benzinga

ALNA Stock Alert: What to Know as Allena Pharmaceuticals Soars 200%

Could there be an epic short squeeze going on with ALNA stock? That's the billion-dollar question as traders target Allena Pharmaceuticals.

5 months ago - InvestorPlace

ALNA Stock Alert: 5 Things to Know as Little-Known Allena Pharmaceuticals Soars 100%

Allena Pharmaceuticals (ALNA) stock is rocketing higher on heavy trading Thursday despite a lack of news from the company. The post ALNA Stock Alert: 5 Things to Know as Little-Known Allena Pharmaceutic...

6 months ago - InvestorPlace

Allena Pharmaceuticals Announces $2.8 Million Registered Direct Offering

NEWTON, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzy...

6 months ago - GlobeNewsWire

Why Are Allena Pharma Shares Plunging Today

An independent data safety monitoring board (DSMB) has conducted the first of two planned Sample Size Reestimations (SSR1) of Phase 3 URIROX-2 Trial of Allena Pharmaceuticals Inc's (NASDAQ: ALNA) reloxa...

8 months ago - Benzinga

Allena Stock Is Surging In Premarket Today As It Explores Strategic, Financing Alternatives

Allena Pharmaceuticals Inc (NASDAQ: ALNA) posted data from the first cohort of the Phase 2 trial (Study 201) evaluating ALLN-346 for hyperuricemia and gout in advanced chronic kidney disease (CKD). The ...

10 months ago - Benzinga

Allena Pharmaceuticals Provides Clinical and Corporate Update

NEWTON, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a late-stage biopharmaceutical company deploying its novel oral biologic platfor...

10 months ago - GlobeNewsWire

Versantis Appoints Mark Fitzpatrick, Seasoned Biotech Executive, as its New CEO

ZURICH--(BUSINESS WIRE)--Versantis has appointed Mark J. Fitzpatrick as Chief Executive Officer (CEO) and member of the board of directors.

11 months ago - Business Wire

Allena Pharmaceuticals, Inc. (ALNA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Allena Pharmaceuticals, Inc. (ALNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisio...

1 year ago - Zacks Investment Research

After Plunging 19.7% in 4 Weeks, Here's Why the Trend Might Reverse for Allena Pharmaceuticals, Inc. (ALNA)

The heavy selling pressure might have exhausted for Allena Pharmaceuticals, Inc. (ALNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall...

1 year ago - Zacks Investment Research

Allena Pharmaceuticals (ALNA) Sees Hammer Chart Pattern: Time to Buy?

Allena Pharmaceuticals (ALNA) has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare Conference

NEWTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and c...

1 year ago - GlobeNewsWire

Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress

NEWTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a late-stage biopharmaceutical company deploying its novel oral biologic platfor...

1 year ago - GlobeNewsWire

Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment...

- Novel oral therapeutic candidate ALLN-346 targets uric acid in the intestinal tract -

1 year ago - GlobeNewsWire

Allena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate Progress

NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a late-stage biopharmaceutical company deploying its novel oral biologic platfor...

1 year ago - GlobeNewsWire

Allena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference

NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

1 year ago - GlobeNewsWire

Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-clas...

1 year ago - GlobeNewsWire

Allena Pharma Stock Under Pressure After Equity Raise Of $28M

Allena Pharmaceuticals Inc (NASDAQ: ALNA) has announced a registered direct offering of 21.3 million shares and warrants to purchase up to 10.7 million shares at $1.311. With gross proceeds of $28 milli...

1 year ago - Benzinga

Allena Pharmaceuticals Announces $28 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

NEWTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enz...

1 year ago - GlobeNewsWire

Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference

NEWTON, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-cla...

1 year ago - GlobeNewsWire

Allena Pharmaceuticals to Host Key Opinion Leader Webinar Focused on ALLN-346 for the Treatment of Gout in Patients w...

Webinar Scheduled for Wednesday, June 16th @ 12 pm EDT Webinar Scheduled for Wednesday, June 16th @ 12 pm EDT

1 year ago - GlobeNewsWire

Moving Average Crossover Alert: Allena Pharmaceuticals (ALNA)

Allena Pharmaceuticals (ALNA) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

1 year ago - Zacks Investment Research

Allena Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

-- Enrollment ongoing in Phase 3 URIROX-2 clinical trial of reloxaliase; interim analysis expected 2Q or 3Q 2022 -- -- Enrolling healthy volunteers in Phase 1b MAD study of ALLN-346; initial data expect...

1 year ago - GlobeNewsWire